Fate Therapeutics Reports Positive Interim Clinical Data from Programs for Patients with Relapsed / Refractory B-cell Lymphoma
Fate Therapeutics, Inc. (NASDAQ: FATE) a clinical-stage biopharmaceutical company which develops programmed cellular immunotherapies for cancer and immune disorders worldwide, reported on Friday positive interim clinical data from the Company’s FT516 and FT596 programs for patients with relapsed / refractory...